Biolargo Stock Price, News & Analysis

BioLargo (OTCQX:BLGO) announced that its subsidiary Clyra Medical Technologies has secured multiple distribution agreements for its medical products in domestic and international markets. While these agreements don't include minimum purchase requirements, they each have the potential to generate significant revenue for Clyra. CEO Dennis P. Calvert highlighted the company's investment in meeting client specifications and bringing products to market, though no specific timeline or sales volume predictions were provided.

BioLargo (OTCQX:BLGO) has revealed case study data demonstrating that its AEC (Aqueous Electrostatic Concentrator) PFAS solution can achieve over 80% lifecycle cost savings compared to traditional carbon-based treatment systems. The technology effectively captures and destroys PFAS contamination to non-detect levels in drinking water, wastewater, and landfill leachate.

The significant cost reduction is attributed to the AEC's ability to generate less PFAS-laden waste compared to conventional methods like granular activated carbon (GAC) and ion exchange resins, coupled with lower replacement costs for treatment materials. Unlike traditional methods, the AEC doesn't suffer from breakthrough or channeling phenomena, particularly with short chain PFAS, leading to reduced maintenance frequency and better PFAS capture efficiency.

BioLargo (OTCQX: BLGO), a cleantech and environmental solutions company, has announced its participation in the upcoming 15th Annual LD Micro Invitational at the Westin Grand Central in New York. The company's President & CEO Dennis P. Calvert will deliver a presentation on April 10, 2025, at 2:30 PM Eastern Time, covering the company's financial performance from the previous year and current business initiatives.

The LD Micro Invitational XV is scheduled for April 9-10, 2025, featuring over 50 presenting companies. The event will commence with registration at 2:00 PM ET on April 9th, followed by keynote speeches. Companies will present in 30-minute segments and participate in private investor meetings throughout the two-day conference.

BioLargo (OTCQX:BLGO) reported record-breaking financial results for 2024, marking its tenth consecutive year of revenue growth. The cleantech company achieved revenues of $17.77 million, representing a 45% increase from 2023. The company's net loss decreased by 6% to $4.34 million, with $3.49 million attributed to Clyra Medical operations.

The company's financial position showed improvement with $3.54 million in cash, total assets of $10.51 million, and stockholders' equity of $6.05 million. BioLargo reduced its reliance on equity financing, issuing 42% fewer shares compared to 2023. The company generated over $5 million from odor control products and continues to develop emerging technologies, including Clyra surgical products, PFAS water treatment solutions, and Cellinity battery storage technology.

BioLargo (OTCQX:BLGO), a developer of sustainable technologies and full-service environmental engineering company, has scheduled its Year-End 2024 earnings results webcast and conference call for Monday, March 31, 2025, at 4:00 PM Eastern Time (1:00 PM Pacific).

The public event will cover the company's financial results for the year ended December 31, 2024, discuss recent milestones, and include a question-and-answer session. Participants can join via webcast or teleconference, with replay access available until July 1, 2025 for the webcast and April 14, 2025 for the teleconference.

BioLargo (OTCQX:BLGO) has been invited to present at the Air & Waste Management Association's 'The Science of PFAS' conference on March 12, 2025. The company will showcase its Aqueous Electrostatic Concentrator (AEC) technology's successful results in removing and destroying PFAS from landfill leachate.

The AEC technology demonstrates unique capabilities in PFAS treatment, achieving 'non-detect' levels (less than 1 part per trillion) for all PFAS types (short, medium, and long-chain), while producing only inert salts as byproducts. The system selectively captures PFAS from water, wastewater, and landfill leachate without generating significant waste.

Tonya Chandler, President of BioLargo Equipment Solutions & Technologies, will present these findings at the conference, which brings together environmental professionals, regulators, and researchers from across 65 countries.

BioLargo (OTCQX:BLGO) reports a successful 2024 with significant achievements across its business segments. The company's stock appreciated from $0.17 to a high of $0.45 in 2024, currently trading at $0.30. Cash balance increased to $3.9 million in Q3 2024 from $3.5 million at 2023 year-end, with shareholders' equity reaching $6.0 million.

Key highlights include the successful expansion of Pooph, their pet odor product line, now available at major retailers including Amazon, Walmart, and Target. The company's medical subsidiary invested over $2 million in preparing Bioclynse wound irrigation solution for surgical applications. Their battery technology subsidiary completed a pilot manufacturing facility, while their water treatment division secured their first commercial PFAS-treatment project.

For 2025, BioLargo aims to uplist to NASDAQ or NYSE, continue revenue growth, launch Bioclynse, expand PFAS treatment systems, and develop commercial-sized Cellinity battery cells. The company achieved zero share dilution in the second half of 2024.

BioLargo Inc. (OTCQX:BLGO) announced that its President and CEO Dennis P. Calvert has been appointed by U.S. Secretary of Commerce Gina Raimondo to serve on the Environmental Technologies Trade Advisory Committee (ETTAC) for the 2024-2026 term. ETTAC advises on trade policies and programs affecting the U.S. environmental technology industry through the Trade Promotion Coordinating Committee (TPCC).

The U.S. environmental technologies sector generates $432 billion in revenue and employs 1.8 million American workers. The committee includes representatives from various environmental sectors including water treatment, air quality control, and waste management.

BioLargo (OTCQX:BLGO) reported strong financial results for Q3 2024, with year-to-date revenues reaching $14.1 million, an 80% increase compared to the same period in 2023. Third-quarter revenue grew 63% to $4.4 million. The company reduced its net loss to $1.1 million for Q3 and $2.6 million year-to-date, improving from $1.5 million and $3.6 million respectively in 2023. As of September 30, 2024, BioLargo held $3.9 million in cash and cash equivalents, with total stockholder's equity at $6.0 million. The company has achieved its tenth consecutive year of record-setting growth.